^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) + plinabulin (BPI 2358) (GEF-H1 activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination.
Published date:
05/25/2023
Excerpt:
DUBLIN-3 (NCT02504489) was a global Phase 3 study in 2nd/3rd line EGFR-wild type, stage IIIB/IV NSCLC pts (N = 559) randomized 1:1 to Plin/Doc or Doc alone....Median OS in each Q was consistently higher with Plin/Doc vs Doc alone, except for Qs with an IS signature. With baseline NLR ≤3.6, PLR≤194, or LMR≥5.9, thus avoiding an IS signature, median OS was on average 2.5 Mo (range 0.6-4.5 Mo) longer with Plin/Doc vs Doc alone.
DOI:
10.1200/JCO.2023.41.16_suppl.e21018
Trial ID:
